Navigation Links
With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
Date:12/13/2010

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that with the introduction of Novartis' Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate major shifts in the landscape of the MS market. One month after the launch of Gilenya, trial and uptake of Extavia, a DMA launched by Novartis one year earlier, continues to be tempered due to the perception that Extavia is a "me too" agent -a perception made even more noticeable by the availability of the new and unique DMA, Gilenya. In fact, compared to previous waves, both current and anticipated patient share of Extavia have decreased due in part to a drop in the number of high prescribers of Extavia.

The recently released fourth and final wave of the LaunchTrends®: Extavia report series finds that the small amount of Extavia use is mostly driven by out-of-pocket cost concerns with other DMAs and that managed care reimbursement is playing less of a role compared to the role it played in the first year of Extavia's commercial availability. In fact, perceptions of the managed care process for Extavia have declined since earlier waves. While Novartis detailing seems to be primarily focused on Gilenya, neurologists who were recently detailed on Extavia are more likely to have experience with the DMA. While anticipated prescribing of Gilenya is expected to rise substantially over the next six months, surveyed neurologists believe that any change in their prescribing of Extavia will be minimal.

LaunchTrends®: Extavia is a four wave syndicated report series designed to track the uptake of Novartis's Extavia at one month, six months, nine months and one year following its commercial availability. In the current wave of research which measures Extavia's market impact after one year, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of 20 of the respondents in November 2010. MS market dynamics will also be measured in upcoming syndicated reports including TreatmentTrends®: Multiple Sclerosis and ChartTrends®: Multiple Sclerosis. BioTrends also recently published the first wave of LaunchTrends®: Gilenya, a report series tracking trial, uptake, and perceptions of Novartis' Gilenya, at one, three and six months post launch. The next wave will be published in February 2011.

About LaunchTrendsLaunchTrends assesses trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Sharon Funk404-223-2963sfunk@bio-trends.com   Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
2. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
3. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
4. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
5. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
6. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
7. New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinsons Disease Drug Development
8. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
9. American Oriental Bioengineering Comments on Recent Property Purchase
10. Recent Advances in Organic Chemistry Using Real-Time In Situ FTIR
11. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a ... Market for Liquid Biopsy is growing rapidly and expected to reach ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a swiftly ... figures and boom in the coming future. There has been a ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
Breaking Biology Technology:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):